pd 142893 has been researched along with pd 156252 in 1 studies
| Studies (pd 142893) | Trials (pd 142893) | Recent Studies (post-2010) (pd 142893) | Studies (pd 156252) | Trials (pd 156252) | Recent Studies (post-2010) (pd 156252) |
|---|---|---|---|---|---|
| 64 | 0 | 3 | 5 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cody, WL; Doherty, AM; Haleen, SJ; He, JX; Reily, MD; Reyner, EL; Stewart, BH; Walker, DM | 1 |
1 other study(ies) available for pd 142893 and pd 156252
| Article | Year |
|---|---|
Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties.
Topics: Amino Acid Sequence; Animals; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Femoral Artery; Humans; In Vitro Techniques; Kinetics; Magnetic Resonance Spectroscopy; Molecular Sequence Data; Muscle Contraction; Muscle, Smooth, Vascular; Oligopeptides; Protein Conformation; Pulmonary Artery; Rabbits; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Renal Circulation; Structure-Activity Relationship; Tumor Cells, Cultured | 1997 |